Enforcing Mental Health Parity
The Biden administration has proposed tightening up enforcement of the federal laws that govern requiring mental health parity, a group of statutes that include the watershed Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 and the Consolidated Appropriations Act of 2021, which requires health plans to perform analyses that compare “nonquantitative treatment limits” (NQTLs) on mental and behavioral health benefits with those for medical and surgical services.
NQTLs include rules governing prior authorization, provider reimbursement rates and provider networks. Under the mental health parity laws, the NQTLs for mental and behavioral services are supposed to be no more restrictive than they are medical and surgical services.
If the administration’s new rules are finalized, they would require health plans to supply more detail in their NQTL comparative analyses. The analyses would have to include, for example, new information comparing claims denials for mental and behavioral health services to denials for medical and surgical services.
Health plans might also be facing new requirements to provide data that will allow regulators to compare their networks of mental and behavioral health providers to their networks of medical and surgical providers. One of the main gaps in mental health parity with respect to health insurance has been the shortage of in-network providers.
A July 2023 enforcement report listed several examples of NQTL shortcomings flagged by federal regulators:
Excluding coverage of residential treatment for mental health and substance use disorders when residential treatment for medical and surgical treatment was covered
Using employee assistance programs (EAPs) as gatekeepers to services for mental health and substance use disorder services when plan members didn’t have go through an EAP to use medical or surgical benefits
Excluding methadone as a treatment for opioid use disorder but covering it for medical and surgical conditions
Not covering inpatient substance use disorder treatment unless the member completes the entire course of treatment when no such requirement exists for medical or surgical treatment.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
